5 High Growth Stocks to Buy and Hold for the Next Decade

Page 1 of 5

In this article, we will list the 5 High Growth Stocks to Buy and Hold for the Next Decade. Please visit 15 High Growth Stocks to Buy and Hold for the Next Decade if you would like to see the extended list and the methodology behind it.

Analyst Explains How NVIDIA (NVDA) Can Reach $8 Trillion Market Cap

5. Roivant Sciences Ltd. (NASDAQ:ROIV)

On May 21, 2026, TD Cowen raised the firm’s price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $41 from $38 and maintained a Buy rating on the shares. TD Cowen said IMVT-1402 toplined impressive Ph2b D2T RA data, with ACR20 of 73%, ACR50 of 55%, and ACR70 of 36%. The firm also said Roivant has many more catalysts ahead.

Citi also raised the firm’s price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $42 from $35 and maintained a Buy rating on the shares. Citi said it sees further upside from Roivant’s second half of 2026 data catalysts and kept the stock as a top pick following the IMVT-1402 data.

A day earlier, Roivant Sciences Ltd. (NASDAQ:ROIV) reported fiscal Q4 EPS of 28c, compared to the consensus estimate of (35c). Revenue totaled $2.52M, versus the consensus estimate of $3.91M. CEO Matt Gline said the positive Period 1 data from the IMVT-1402 trial in D2T RA showed “exciting potential” for a new treatment approach in RA patients who have failed multiple prior therapies. Gline also pointed to the FDA’s Breakthrough Therapy Designation for brepocitinib in cutaneous sarcoidosis and said the company expects several second-half 2026 updates, including brepocitinib’s expected launch in DM by the end of September and data in NIU, CLE, PH-ILD, and D2T RA.

Roivant Sciences Ltd. (NASDAQ:ROIV) focuses on the discovery, development, and commercialization of medicines and technologies.

Page 1 of 5
1281292 - 11759070 - 1